Diabetic nephropathy in children and adolescents: a critical review with particular reference to angiotensin-converting enzyme inhibitors.
Clinical diabetic nephropathy is a well-recognized cause of increased morbidity and mortality in patients with type 1 diabetes. The finding that microalbuminuria predicts progression to overt nephropathy has allowed early diagnosis and preventive interventions. Several studies have demonstrated that treatment with angiotensin-converting enzyme (ACE) inhibitors slows down the rate of decline of the glomerular filtration rate in type 1 diabetes patients with established proteinuria. The renoprotective properties of the ACE inhibitor captopril extend beyond its antihypertensive effects. ACE inhibitors represent the most appropriate class of antihypertensive drugs for treating type I diabetes patients because of their efficacy and safety. When microalbuminuria is detected and confirmed in a diabetic child or adolescent, and if it persists despite 6-12 months of improved metabolic control, treatment with ACE inhibitors should be started, even if the child is normotensive. Careful follow-up of renal function is essential.
Chiarelli
F
F
Department of Paediatrics, University of Chieti, Italy.
Casani
A
A
Verrotti
A
A
Morgese
G
G
Pinelli
L
L
D000293:Adolescent; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D004044:Dietary Proteins / Q000008:administration & dosage; D006801:Humans; D007328:Insulin / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D004044:Dietary Proteins; D007328:Insulin; D002216:Captopril